DBVT

Dbv Technologies SA

Add to Watchlist

Advanced Chart

9.280

-0.224(-2.357%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

9.500

Open

9.500

VWAP

9.31

Vol

9.75K

Mkt Cap

1.27B

Low

9.1312

Amount

90.70K

EV/EBITDA(TTM)

Total Shares

96.24M

246.41M

EV/OCF(TTM)

P/S(TTM)

46.40

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

765.11K

+36.85%

751.70K

-31.68%

749.29K

-35.51%

Estimates Revision

The market is revising Upward the revenue expectations for DBV Technologies S.A. (DBVT) for FY2025, with the revenue forecasts being adjusted by 18.45% over the past three months. During the same period, the stock price has changed by 0.22%.

Revenue Estimates for FY2025

Revise Upward

+18.45%

In Past 3 Month

Stock Price

Go Up

+0.22%

In Past 3 Month

4 Analyst Rating

70.37% Upside

Wall Street analysts forecast DBVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DBVT is 15.81 USD with a low forecast of 7.25 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

1 Sell

Moderate Buy

70.37% Upside

Current: 9.280

Low

7.25

Averages

15.81

High

21.00

70.37% Upside

Current: 9.280

Low

7.25

Averages

15.81

High

21.00

Goldman Sachs

Rajan Sharma

reinstated

$7.25

2025-05-29

Reason

Goldman Sachs

Rajan Sharma

Price Target

$7.25

2025-05-29

reinstated

Reason

Citizens JMP

Outperform

maintain

$15 -> $21

2025-05-27

Reason

Citizens JMP

Price Target

$15 -> $21

2025-05-27

maintain

Outperform

Reason

Citizens JMP raised the firm's price target on DBV Technologies to $21 from $15 and keeps an Outperform rating on the shares. Xolair's food allergy launch has more than 50K patients on drug within the first year despite some key hindrances, which may be limiting its use in Viaskin Peanut's target 1-7 year old population, the analyst tells investors in a research note. The firm sees the Phase 3 VITESSE data in 4-7 year olds in Q4 as the next key catalyst for shares.

Citizens Capital Markets

Jonathan Wolleben

Buy

Reiterates

$10

2025-03-04

Reason

Citizens Capital Markets

Jonathan Wolleben

Price Target

$10

2025-03-04

Reiterates

Buy

Reason

JMP Securities

Jonathan Wolleben

Buy

Reiterates

$10

2025-01-10

Reason

JMP Securities

Jonathan Wolleben

Price Target

$10

2025-01-10

Reiterates

Buy

Reason

JMP Securities

Jonathan Wolleben

Buy

Reiterates

$10

2024-12-10

Reason

JMP Securities

Jonathan Wolleben

Price Target

$10

2024-12-10

Reiterates

Buy

Reason

HC Wainwright & Co.

Andrew Fein

Strong Buy

Maintains

$5 → $7

2024-10-24

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$5 → $7

2024-10-24

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Dbv Technologies SA (DBVT.O) is -5.46, compared to its 5-year average forward P/E of -3.31. For a more detailed relative valuation and DCF analysis to assess Dbv Technologies SA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.31

Current PE

-5.46

Overvalued PE

-1.71

Undervalued PE

-4.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.49

Current EV/EBITDA

-1.83

Overvalued EV/EBITDA

0.16

Undervalued EV/EBITDA

-3.14

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued

5Y Average PS

43.86

Current PS

86.48

Overvalued PS

71.38

Undervalued PS

16.35

Financials

Annual

Quarterly

FY2025Q1

YoY :

-46.48%

753.00K

Total Revenue

FY2025Q1

YoY :

-6.79%

-26.62M

Operating Profit

FY2025Q1

YoY :

-0.62%

-27.08M

Net Income after Tax

FY2025Q1

YoY :

-7.14%

-0.26

EPS - Diluted

FY2025Q1

YoY :

-45.38%

-19.68M

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

+305.14%

-2.59K

FCF Margin - %

FY2025Q1

YoY :

+85.69%

-3.60K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

2.3K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.5M

Volume

6-9

Months

1.5M

Volume

0-12

Months

0.0

Volume

Bought

0-3

162.0K

Volume

Months

3-6

749.4K

Volume

Months

6-9

50.0K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

2.3K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

DBVT News & Events

Events Timeline

2025-07-22 (ET)

2025-07-22

16:48:21

DBV Technologies appoints James Briggs as chief human resources officer

2025-06-25 (ET)

2025-06-25

16:19:01

DBV Technologies announces first subject screened in COMFORT Toddlers trial

2025-03-24 (ET)

2025-03-24

11:32:54

DBV sinks after disclosing 'substantial doubt' of going concern

News

9.0

06-25Newsfilter

DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old

1.0

06-12Newsfilter

DBV Technologies to Participate in Upcoming EAACI Congress 2025

7.5

06-04Newsfilter

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 30, 2025

People Also Watch

VMCA

Valuence Merger Corp I

SHENGFENG DEVELOPMENT Ltd

AI Transportation Acquisition Corp

FAQ

What is Dbv Technologies SA (DBVT) stock price today?

The current price of DBVT is 9.28 USD — it has decreased -2.36 % in the last trading day.

DBVT

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

DBVT News & Events

Events Timeline

News

People Also Watch

FAQ

What is Dbv Technologies SA (DBVT) stock price today?

What is Dbv Technologies SA (DBVT)'s business?

What is the price predicton of DBVT Stock?

What is Dbv Technologies SA (DBVT)'s revenue for the last quarter?

What is Dbv Technologies SA (DBVT)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Dbv Technologies SA (DBVT)'s fundamentals?

How many employees does Dbv Technologies SA (DBVT). have?

What is Dbv Technologies SA (DBVT) market cap?